This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Merck Inks $3.3B Licensing Deal With Chinese Biotech for Cancer Therapy
by Zacks Equity Research
MRK in-licenses a bispecific antibody, based on the same mechanism as SMMT's lead drug, which outperformed its blockbuster drug, Keytruda, in a lung cancer study.
MRKPositive Net Change SMMTPositive Net Change TILNegative Net Change BNTXPositive Net Change
biotechs medical pharmaceuticals
Trump Taps RFK for HHS: Time to Avoid Biotech?
by Andrew Rocco
With Trump's appointment of Robert F. Kennedy Jr. as the secretary of Health and Human Services, the biotech industry has more questions than answers. Stock Strategist Andrew Rocco explains.
PFEPositive Net Change NVOPositive Net Change MCDNegative Net Change MRNAPositive Net Change XBIPositive Net Change
biotechnology biotechs
Kodiak Q3 Loss Narrower Than Expected, Pipeline Development in Focus
by Zacks Equity Research
KOD reports a narrower-than-expected loss for the third quarter of 2024. The company provides updates regarding its pipeline development plans.
NVSPositive Net Change PFEPositive Net Change KODPositive Net Change ALLOPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe
by Zacks Equity Research
The CHMP renders a positive opinion recommending approval for BIIB and Eisai's Leqembi for treating early Alzheimer's disease.
BIIBPositive Net Change LLYPositive Net Change PRTAPositive Net Change
biotechs
Vaccine Stocks Fall After Trump Selects RFK Jr. to Lead HHS
by Sundeep Ganoria
President-elect Donald Trump picks Robert F. Kennedy Jr., a prominent vaccine skeptic, as the next health secretary of the HHS.
PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change BNTXPositive Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Amgen Shrugs Off Bone Density Concerns Related to Obesity Candidate
by Zacks Equity Research
AMGN says there was no connection between the administration of MariTide and bone mineral density changes.
NVOPositive Net Change LLYPositive Net Change AMGNPositive Net Change VKTXNegative Net Change
biotechs
Biotech Stock Roundup: NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study Data
by Zacks Equity Research
NVAX and RNA are in the spotlight following Q3 results and study data, respectively.
NVAXPositive Net Change RNAPositive Net Change SNDXPositive Net Change
biotechnology biotechs medical pharmaceuticals
The PNC Financial Services Group (PNC) Up 10.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
The PNC Financial Services Group (PNC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PNCNegative Net Change WFCNegative Net Change
aerospace airlines auto-tires-trucks basic-materials benefits-of-zacks biotechs bitcoin brics business-services communications computers construction consumer-discretionary consumer-staples earnings emerging-markets etfs fang finance industrial-products insurance internet internet-content medical multi-sector-conglomerates mutual-funds oil-energy pharmaceuticals reit semiconductor transportation utilities
Why Is Goldman (GS) Up 12.2% Since Last Earnings Report?
by Zacks Equity Research
Goldman (GS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
GSNegative Net Change
aerospace airlines auto-tires-trucks basic-materials benefits-of-zacks biotechs bitcoin brics business-services communications computers construction consumer-discretionary consumer-staples earnings emerging-markets etfs fang finance industrial-products insurance internet internet-content medical multi-sector-conglomerates mutual-funds oil-energy pharmaceuticals reit semiconductor transportation utilities
BNTX to Boost Oncology Pipeline With Biotheus Acquisition, Stock Up
by Zacks Equity Research
BioNTech inks a deal to acquire Biotheus and gain full global rights to a bispecific antibody, BNT327/PM8002, being studied for various oncology indications.
SMMTPositive Net Change TILNegative Net Change CSTLPositive Net Change BNTXPositive Net Change
biotechs
Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal
by Zacks Equity Research
SYRS stock plummets as late-stage cancer study of lead candidate fails to achieve its primary endpoint leading to the termination of the study.
BIIBPositive Net Change ABBVPositive Net Change ALLOPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
RNA Stock Hits Record High on Entering the Cardiac Disease Space
by Zacks Equity Research
Avidity Biosciences expands its pipeline to include two new drugs targeting rare genetic cardiomyopathies.
BIIBPositive Net Change RNAPositive Net Change CSTLPositive Net Change
biotechs medical pharmaceuticals
Theravance's Q3 Loss Narrower Than Expected, Revenues Rise Y/Y
by Zacks Equity Research
TBPH beats third-quarter estimates for both sales and earnings. Increased collaboration revenues from Viatris drive year-over-year top-line performance.
BIIBPositive Net Change TBPHPositive Net Change ALLOPositive Net Change VTRSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
FATE Q3 Earnings Beat on Higher Revenues, Pipeline in Focus
by Zacks Equity Research
FATE reports a narrower-than-expected loss on higher revenues for the third quarter of 2024. The company's innovative pipeline is in focus.
ANIPNegative Net Change FATEPositive Net Change CSTLPositive Net Change IMCRNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Axsome's Q3 Earnings Beat, Auvelity Drives Sales Growth, Stock Up
by Zacks Equity Research
AXSM posts better-than-expected third-quarter results. Stock rises in response to the results and strong sales uptake of Auvelity.
JAZZPositive Net Change ANIPNegative Net Change AXSMPositive Net Change CSTLPositive Net Change
biotechs earnings
Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus
by Zacks Equity Research
XENE reports a narrower-than-expected third-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD are progressing well.
BIIBPositive Net Change NBIXPositive Net Change XENEPositive Net Change ALLOPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
SpringWorks' Q3 Loss Narrower Than Expected, Revenues Miss Mark
by Zacks Equity Research
SWTX reports mixed third-quarter 2024 results. Its newly approved desmoid tumor drug, Ogsiveo, witnesses a strong launch.
ANIPNegative Net Change CSTLPositive Net Change IMCRNegative Net Change
biotechs earnings
Novavax Q3 Earnings & Sales Beat, Stock Falls 6% on '24 View Cut
by Zacks Equity Research
NVAX reports encouraging third-quarter results. However, the stock falls due to management lowering its sales guidance, citing lower COVID-19 vaccine uptake.
SNYPositive Net Change BIIBPositive Net Change NVAXPositive Net Change CSTLPositive Net Change
biotechs earnings medical messenger-rna pharmaceuticals vaccines
Prothena Q3 Earnings Beat Estimates, Pipeline Progress in Focus
by Zacks Equity Research
PRTA posts a narrower-than-expected loss in the third quarter. The company also reports encouraging pipeline progress for the quarter.
RHHBYPositive Net Change BMYPositive Net Change NVOPositive Net Change PRTAPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Repligen Beats on Q3 Earnings & Sales, Narrows '24 Sales View
by Zacks Equity Research
RGEN reports better-than-expected third-quarter results. While management lowers its guidance for 2024 total sales, it raises the same for EPS.
BIIBPositive Net Change RGENNegative Net Change FOLDPositive Net Change CSTLPositive Net Change
biotechs earnings medical
Bayer Q3 Earnings Miss Estimates, Nubeqa, Kerendia Boost Sales
by Zacks Equity Research
BAYRY's third-quarter earnings get affected due to impairment losses at the Crop Science division. Sales gain from the Pharmaceutical business's strong performance.
REGNPositive Net Change JNJPositive Net Change BAYRYPositive Net Change
biotechnology biotechs earnings pharmaceuticals
Mirum's Q3 Earnings Beat Estimates, 2024 Revenue View Raised
by Zacks Equity Research
MIRM's third-quarter 2024 earnings and revenues surpass estimates. The company increases revenue guidance for 2024. Stock rises in pre-market.
ANIPNegative Net Change MIRMPositive Net Change CSTLPositive Net Change IMCRNegative Net Change
biotechs earnings
AbbVie Stock Declines as Schizophrenia Studies Fail, BMY Gains
by Zacks Equity Research
ABBV stock tumbles 13% after two mid-stage schizophrenia studies on emraclidine fail to meet their primary endpoint. BMY stock rises.
BIIBPositive Net Change BMYPositive Net Change ABBVPositive Net Change ALLOPositive Net Change
biotechnology biotechs medical pharmaceuticals
Bristol Myers Stock Trading Near 52-Week High: Time to Buy or Sell?
by Ekta Bagri
BMY has been having a good run for the past three months. The stock recently touched a 52-week high. We believe there is more room for growth, and any dip in share price can be used as a buying opportunity.
BMYPositive Net Change PFEPositive Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Will These 5 Biotech Stocks Surpass Q3 Earnings Forecasts?
by Ahan Chakraborty
Let's look at five biotech and drug companies, AZN, NVAX, AXSM, TBPH and PRTA, slated to release their third-quarter 2024 results this week.
AZNPositive Net Change NVAXPositive Net Change PRTAPositive Net Change TBPHPositive Net Change AXSMPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals